This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Masson K, Rönnstrand L . Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal 2009; 21: 1717–1726.
Jones AV, Cross NCP . Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 2004; 61: 2912–2923.
Reiter A, Walz C, Cross NCP . Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Curr Drug Targets 2007; 8: 205–216.
Liu YC, Sashida G, Kodama A, Ohyashiki K . Translocation (4;9)(q11;q33), a new rearrangement in acute myeloid leukemia with central nervous system involvement. Cancer Genet Cytogenet 2006; 165: 85–86.
Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20: 827–832.
Guasch G, Mack GJ, Popovici C, Dastugue N, Birnbaum D, Rattner JB et al. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood 2000; 95: 1788–1796.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Grand, F., Waghorn, K., Ernst, T. et al. The t(4;9)(q11;q33) fuses CEP110 to KIT in a case of acute myeloid leukemia. Leukemia 25, 1049–1050 (2011). https://doi.org/10.1038/leu.2011.40
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.40